capon, ariad, CFMT

REVERSED

1600 Biotechnology and Organic Chemistry
1612 Ex Parte Platz et al 11/536,348 ADAMS 103(a) NOVARTIS EXAMINER KISHORE, GOLLAMUDI S

1655 Ex Parte Chern et al 11/999,637 FREDMAN 112(1) Cozen O'Connor EXAMINER MI, QIUWEN

“[T]he determination of what is needed to support generic claims to biological subject matter depends on a variety of factors, such as the existing knowledge in the particular field, the extent and content of the prior art, the maturity of the science or technology, the predictability of the aspect at issue, and other considerations appropriate to the subject matter.” Capon v. Eshhar, 418 F.3d 1349, 1359 (Fed. Cir. 2005).

Capon v. Eshhar, 418 F.3d 1349, 76 USPQ2d 1078 (Fed. Cir. 2005) . . . . . . . . . .2163
In Ariad, the court found that the written description “doctrine never created a heightened requirement to provide a nucleotide-by-nucleotide recitation of the entire genus of claimed genetic material; it has always expressly permitted the disclosure of structural features common to the members of the genus.” Ariad Pharmaceuticals, Inc. v. Eli Lilly and Co., 598 F.3d 1336, 1352 (Fed. Cir. 2010).

2100 Computer Architecture and Software
2169 Ex Parte Thusoo 10/662,095 ZECHER 103(a) HICKMAN PALERMO TRUONG & BECKER/ORACLE EXAMINER BETIT, JACOB F

2600 Communications
2618 Ex Parte Weber et al 11/559,382 MACDONALD 102(e)/103(a) 37 C.F.R. § 41.50(b) 103(a) Paradigm IP Law, PC EXAMINER TRINH, TAN H

3600 Transportation, Construction, Electronic Commerce, Agriculture, National Security, and License & Review
3633 Ex Parte Pierson et al 11/100,145 SAINDON 102(b)/103(a) FAY SHARPE LLP EXAMINER A, PHI DIEU TRAN

3700 Mechanical Engineering, Manufacturing, and Products & Design
3732 Ex Parte Pernot et al 10/580,373 BAHR 103(a) Gary M Cohen EXAMINER WILSON, JOHN J

3761 Ex Parte Venkitaraman et al 11/128,579 HORNER 103(a) 37 C.F.R. § 41.50(b) 103(a) THE PROCTER & GAMBLE COMPANY EXAMINER TREYGER, ILYA Y
AFFIRMED-IN-PART

3700 Mechanical Engineering, Manufacturing, and Products & Design
3781 Ex Parte Hall et al 10/418,925 PRATS 102(b) 102(b)/103(a) Evans & Dixon, LLC EXAMINER SMALLEY, JAMES N
AFFIRMED

1600 Biotechnology and Organic Chemistry
1654 Ex Parte Aoki et al 10/461,829 SCHEINER 103(a) 37 C.F.R. § 41.50(b) 103(a) STEPHEN DONOVAN ALLERGAN, INC. EXAMINER GUPTA, ANISH

“Enablement does not require an inventor to meet lofty standards for success in the commercial marketplace. Title 35 does not require that a patent disclosure enable one of ordinary skill in the art to make and use a perfected, commercially viable embodiment absent a claim limitation to that effect.” CFMT, Inc. v. Yieldup Int’l Corp., 349 F.3d 1333, 1338 (Fed. Cir. 2003).

CFMT, Inc. v. Yieldup Int ’l Corp., 349 F.3d 1333, 68 USPQ2d 1940 (Fed. Cir. 2003). . . . . . . . . . . . . . . . 2164

2100 Computer Architecture and Software
2116 Ex Parte Leech et al 11/045,965 BARRY 103(a) HEWLETT-PACKARD COMPANY EXAMINER DU, THUAN N

2400 Networking, Mulitplexing, Cable, and Security
2431 Ex Parte Romines et al 11/086,183 BROCKETTI 103(a) Law Office of Jim Boice EXAMINER SU, SARAH

2455 Ex Parte Rosenstock et al 10/676,744 DANG 103(a) HARNESS, DICKEY & PIERCE, P.L.C. EXAMINER LAZARO, DAVID R

2455 Ex Parte Rosenstock et al 10/676,746 DANG 103(a) HARNESS, DICKEY & PIERCE, P.L.C. EXAMINER LAZARO, DAVID R

3600 Transportation, Construction, Electronic Commerce, Agriculture, National Security, and License & Review
3653 Ex Parte Jones et al 09/967,232 SAINDON 112(2)/103(a) CUMMINS-ALLISON CORP. C/O NIXON PEABODY LLP EXAMINER SHAPIRO, JEFFERY A
REHEARING

DENIED

1600 Biotechnology and Organic Chemistry
1643 Ex Parte King et al 10/731,759 MILLS 103(a) COZEN O'CONNOR, P.C. EXAMINER SANG, HONG